Dataset Information


Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)-T Cells.

ABSTRACT: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized adoptive cell therapy with impressive therapeutic outcomes of >80% complete remission (CR) rates in some haematological malignancies. Despite this, CAR T cell therapy for the treatment of solid tumours has invariably been unsuccessful in the clinic. Immunosuppressive factors and metabolic stresses in the tumour microenvironment (TME) result in the dysfunction and exhaustion of CAR T cells. A growing body of evidence demonstrates the importance of the mitochondrial and metabolic state of CAR T cells prior to infusion into patients. The different T cell subtypes utilise distinct metabolic pathways to fulfil their energy demands associated with their function. The reprogramming of CAR T cell metabolism is a viable approach to manufacture CAR T cells with superior antitumour functions and increased longevity, whilst also facilitating their adaptation to the nutrient restricted TME. This review discusses the mitochondrial and metabolic state of T cells, and describes the potential of the latest metabolic interventions to maximise CAR T cell efficacy for solid tumours.

PROVIDER: S-EPMC8002030 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC6405971 | BioStudies
| S-EPMC8053711 | BioStudies
| S-EPMC8461872 | BioStudies
| S-EPMC7236186 | BioStudies
| S-EPMC8354246 | BioStudies
| S-EPMC8782435 | BioStudies
| S-EPMC8082048 | BioStudies
| S-SCDT-EMBOJ-2019-103637 | BioStudies
| S-EPMC6960448 | BioStudies
| S-EPMC5744429 | BioStudies